Search Results: keywords:"drug competition"

  • S. 1040 — To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
    Status:Reported to Senate
    Words:2,917

    S. 1040 aims to alter the Federal Trade Commission Act to stop pharmaceutical companies from engaging in "product hopping." This practice involves making minor changes to a drug, like reformulating it, to extend patent protections and delay generic versions from entering the...

    Simple Explanation

    S. 1040 is a proposed law that wants to stop medicine companies from slightly changing their medicines just to keep other companies from making less expensive versions. It tells the rules so everyone plays fair and doesn’t cheat by removing old medicines to make people buy new ones.

  • S. 1040 — To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
    Status:Introduced in Senate
    Words:2,835

    S. 1040 is a bill titled the "Drug Competition Enhancement Act" that aims to modify the Federal Trade Commission Act to prohibit a practice known as "product hopping." Product hopping is when a drug manufacturer makes minor changes to a drug to extend its market exclusivity...

    Simple Explanation

    S. 1040 is a rule that tries to stop medicine makers from making tiny changes to their drugs just to keep other companies from making cheaper versions. It lets a special group check if this is happening and make sure everyone plays fair.